CDW (CDW) Q2 Revenue Jumps 10%

CDW reported strong Q2 2025 results, with GAAP revenue of $5,976.6 million, up 10.2% year-over-year, and Non-GAAP EPS of $2.60, up 3.9% year-over-year, both surpassing analyst estimates, driven by robust demand in commercial businesses and healthcare. However, profitability faced headwinds as GAAP gross profit margin declined 1.0 percentage point to 20.8% due to a shift towards lower-margin hardware and rising operating expenses, resulting in a 3.5% year-over-year decrease in GAAP net income. Despite the revenue beat, management maintained its cautious full-year guidance, citing ongoing uncertainties in government spending and education sector volatility.

Analysis

CDW Corporation reported a mixed but fundamentally strong Q2 2025, characterized by significant top-line outperformance offset by margin compression and a cautious outlook. GAAP revenue grew 10.2% year-over-year to $5.98 billion, substantially beating estimates by $464 million, while Non-GAAP EPS rose 3.9% to $2.60, also ahead of consensus. This growth was driven by robust demand in its commercial segments, with Corporate sales up 17.6% and Healthcare surging 24.1%, fueled by hardware refresh cycles linked to Microsoft's Windows 10 end-of-life and broader digital transformation initiatives. However, this shift towards lower-margin hardware diluted profitability, causing the GAAP gross profit margin to contract by 1.0 percentage point to 20.8% and contributing to a 3.5% year-over-year decline in GAAP net income to $271 million. Despite the strong quarterly beat, management reiterated, but did not raise, its full-year guidance, projecting low-single-digit Non-GAAP EPS growth. This conservatism reflects persistent challenges, including a 10.9% sales drop in the Education segment due to order pull-forwards and sluggish 2.7% growth in the Government segment amid budget friction.

Key Decisions for Investors

• Investors should closely monitor gross margin trends, as the ongoing sales mix shift towards lower-margin hardware presents a key risk to profitability despite strong top-line momentum.
• The decision to maintain full-year guidance despite the significant Q2 revenue and EPS beat signals management's caution; scrutinize future commentary on government and corporate spending cycles for signs of deceleration.
• Given the divergence in segment performance, consider whether strong growth in the Corporate and Healthcare channels can sustainably offset the pronounced volatility in Education and the persistent sluggishness in Government sales.
• Evaluate the capital return program in the context of declining GAAP net income and moderating free cash flow, as these factors could influence the future pace of share repurchases and dividend increases.